EyeGate launches dry eye trial
Eyegate Pharma has launched a phase 3 clinical trial for its drug target to treat dry eye syndrome, called EGP-437 . The drug candidate is a type of steroid, delivered using the company’s proprietary, non-invasive delivery system, known as Eyegate II.
The Waltham, Mass.-based privately-held biotechnology company said that its previous phase 2 study of the potential therapy found significant improvements in the signs and symptoms of dry eye during and after exposure to adverse environmental conditions.
Stephen From, President and Chief Executive Officer of EyeGate Pharma, said in a statement, “Based on clinical data, we recognize the potential value that EGP-437 may offer patients. Thus, we are excited to initiate this important pivotal study, which moves the Company one step closer to submitting a New Drug Application (NDA).”
No comments:
Post a Comment